BioCentury | May 15, 2014
Distillery Techniques

Technology: Markers

...control vector. In an additional cohort of 13 patients receiving both ProstVac-VF and the radiopharmaceutical Quadramet...
...rilimogene galvacirepvec in Phase III testing to treat prostate cancer. Jazz Pharmaceuticals plc markets Quadramet samarium 153 lexidronam...
BioCentury | May 21, 2012
Clinical News

ProstVac: Interim Phase II data

...with bone metastases who were previously treated with docetaxel showed that ProstVac in combination with Quadramet...
...Quadramet vs. 60 days for Quadramet alone. Additionally, 4 of 17 patients receiving ProstVac plus Quadramet...
...of Quadramet alone. The trial plans to enroll 68 patients to receive 1 mCi/kg IV Quadramet...
BioCentury | May 18, 2012
Clinical News

Bavarian Nordic reports ProstVac data

...Quadramet led to a progression-free survival rate at four months of 29.4% vs. 11.8% for Quadramet...
...bone metastases. Median PFS was 117 days for ProstVac plus Quadramet vs. 60 days for Quadramet...
...therapy in the Phase III PROSPECT trial of ProstVac. EUSA Pharma Inc. (Langhorne, Pa.) markets Quadramet...
BioCentury | Feb 16, 2009
Clinical News

Quadramet: Final Phase I data

...Final data from 24 evaluable patients in an open-label, dose-escalation Phase I trial showed that Quadramet...
...2 minimal responses. The trial enrolled 39 patients who received 0.25, 0.5 or 1 mCi/kg Quadramet...
...dose (MTD) of Quadramet with 1.3 mg/m 2 Velcade was 0.5 mCi/kg. The MTD of Quadramet...
BioCentury | Mar 17, 2008
Finance

Ebb & Flow

...a monoclonal antibody-based agent to image the extent and spread of prostate cancer; and Quadramet...
BioCentury | Mar 17, 2008
Company News

Cytogen, EUSA deal

...membrane antigen ( PSMA ) to image the extent and spread of prostate cancer; Quadramet samarium 153 lexidronam...
BioCentury | Mar 12, 2008
Financial News

EUSA raising $50 million, acquiring Cytogen

...ProstaScint III-indium capromab pendetide used to image the extent and spread of prostate cancer; Quadramet samarium 153 lexidronam...
BioCentury | Nov 12, 2007
Company News

Cytogen cancer, proteomics, diagnostic news

...million. At Sept. 30, CYTO had $17 million in cash. CYTO's sales are led by Quadramet...
BioCentury | Jul 2, 2007
Clinical News

Quadramet: Updated Phase I data

...MM showed that 15 patients achieved a response or disease stabilization after treatment with IV Quadramet...
...June 12, 2006). Cytogen Corp. (CYTO), Princeton, N.J. GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K. Product: Quadramet...
BioCentury | Jun 11, 2007
Clinical News

Quadramet: Phase II data

...In an investigator-sponsored Phase II trial in 43 patients, Quadramet plus docetaxel produced median PSA progression-free...
...Oncology meeting in Chicago. Taxotere docetaxel is marketed by sanofi-aventis Group (Euronext:SAN; SNY, Paris, France). Quadramet...
...metastatic bone lesions. Cytogen Corp. (CYTO), Princeton, N.J. GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K. Product: Quadramet...
Items per page:
1 - 10 of 68